ESMO 2023 Highlights

Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer. Read More ›

Madrid, Spain—Treatment with selpercatinib (Retevmo), a highly selective and potent RET inhibitor, resulted in a statistically significant improvement in progression-free survival compared with the multikinase inhibitors cabozantinib (Cabometyx) or vandetanib (Caprelsa) in the first-line treatment of patients with advanced or metastatic RET mutation–positive medullary thyroid cancer. Read More ›

Madrid, Spain—Results from 3 phase 3 clinical trials demonstrated the superiority of targeted therapies over conventional chemotherapy in patients with oncogene-addicted non–small cell lung cancer (NSCLC), including ALK-positive advanced NSCLC; EGFR exon 20 insertion-mutation–positive, newly diagnosed or advanced NSCLC; and advanced RET fusion–positive NSCLC. These findings were reported during the European Society for Medical Oncology Congress 2023. Read More ›